JNCCN 360 - Hepatobiliary - Available Clinical Trials

Editor:

Al B. Benson III, MD, FACP, FASCO

Advertisement

Advertisement

Available Clinical Trials

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment

Liver Cancer Disparities in American Indian and Alaska Native Persons

Phase III Study of Toripalimab (JS001) Combined With Lenvatinib for Advanced HCC

Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Sections

NCCN Resources

Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.